Leerink Partnrs Has Negative Outlook for FULC Q1 Earnings

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) – Leerink Partnrs cut their Q1 2025 earnings per share (EPS) estimates for Fulcrum Therapeutics in a report issued on Tuesday, February 25th. Leerink Partnrs analyst J. Schwartz now expects that the company will post earnings of ($0.35) per share for the quarter, down from their previous estimate of ($0.30). The consensus estimate for Fulcrum Therapeutics’ current full-year earnings is ($0.16) per share. Leerink Partnrs also issued estimates for Fulcrum Therapeutics’ Q2 2025 earnings at ($0.34) EPS, Q3 2025 earnings at ($0.33) EPS, Q4 2025 earnings at ($0.32) EPS, FY2025 earnings at ($1.32) EPS and FY2026 earnings at ($1.19) EPS.

Fulcrum Therapeutics (NASDAQ:FULC) last released its earnings results on Tuesday, February 25th. The company reported ($0.31) earnings per share for the quarter, missing the consensus estimate of ($0.28) by ($0.03).

FULC has been the topic of a number of other reports. HC Wainwright reissued a “neutral” rating and set a $4.00 target price on shares of Fulcrum Therapeutics in a report on Wednesday. Royal Bank of Canada reiterated a “sector perform” rating and set a $4.00 price target on shares of Fulcrum Therapeutics in a research report on Thursday, November 14th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and three have given a buy rating to the stock. According to MarketBeat, the company has an average rating of “Hold” and an average price target of $9.33.

Fulcrum Therapeutics Trading Up 1.5 %

FULC stock opened at $3.37 on Friday. The firm has a market cap of $181.77 million, a P/E ratio of -10.87 and a beta of 2.03. The stock’s 50 day simple moving average is $4.12 and its 200 day simple moving average is $4.61. Fulcrum Therapeutics has a 12-month low of $2.86 and a 12-month high of $13.70.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Suvretta Capital Management LLC lifted its holdings in shares of Fulcrum Therapeutics by 182.3% in the fourth quarter. Suvretta Capital Management LLC now owns 3,338,466 shares of the company’s stock valued at $15,691,000 after purchasing an additional 2,155,675 shares in the last quarter. Adage Capital Partners GP L.L.C. raised its position in Fulcrum Therapeutics by 50.0% during the fourth quarter. Adage Capital Partners GP L.L.C. now owns 3,000,000 shares of the company’s stock valued at $14,100,000 after buying an additional 1,000,000 shares during the period. State Street Corp lifted its stake in Fulcrum Therapeutics by 61.4% in the 3rd quarter. State Street Corp now owns 1,680,229 shares of the company’s stock worth $5,998,000 after acquiring an additional 638,955 shares in the last quarter. Woodline Partners LP boosted its position in Fulcrum Therapeutics by 110.3% during the 4th quarter. Woodline Partners LP now owns 1,410,520 shares of the company’s stock worth $6,629,000 after acquiring an additional 739,713 shares during the period. Finally, Geode Capital Management LLC grew its stake in Fulcrum Therapeutics by 1.0% during the 3rd quarter. Geode Capital Management LLC now owns 1,320,862 shares of the company’s stock valued at $4,716,000 after acquiring an additional 13,485 shares in the last quarter. 89.83% of the stock is currently owned by institutional investors and hedge funds.

About Fulcrum Therapeutics

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.